
Sign up to save your podcasts
Or


What do we call it when someone with high-risk practices becomes viraemic again after treatment? In this episode, experts discuss the challenges of managing Hepatitis C in people who inject drugs (PWID) and other high-risk groups. Topics include SVR confirmation rates, DAA prescribing practices, acute vs. chronic infection, and real-world reinfection data. Are traditional labels still meaningful or do we need new frameworks for 2025?
Moderator: Ahmed Elsharkawy
Speakers: Ashley Brown, Tatyana Kushner and Sabela Lens
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
By European Association for the Study of the LiverWhat do we call it when someone with high-risk practices becomes viraemic again after treatment? In this episode, experts discuss the challenges of managing Hepatitis C in people who inject drugs (PWID) and other high-risk groups. Topics include SVR confirmation rates, DAA prescribing practices, acute vs. chronic infection, and real-world reinfection data. Are traditional labels still meaningful or do we need new frameworks for 2025?
Moderator: Ahmed Elsharkawy
Speakers: Ashley Brown, Tatyana Kushner and Sabela Lens
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.

7,709 Listeners

135 Listeners

318 Listeners

494 Listeners

68 Listeners

763 Listeners

8 Listeners

0 Listeners

138 Listeners

1,151 Listeners

195 Listeners

87 Listeners

511 Listeners

369 Listeners

0 Listeners